

## THC BioMed Form 7

### MONTHLY PROGRESS REPORT

September 2020

Name of CSE Issuer **THC BioMed Intl Ltd. ("THC BioMed")**  
Trading Symbol: **THC**  
Number of Outstanding Listed Securities **158,426,056 common shares and 47,774,529 reserved for Issuance**  
Date: **October 6, 2020**

#### Report on Business

1. Provide a general overview and discussion of the development of the Issuer's business and operations over the previous month. Where the Issuer was inactive disclose this fact.

**During the period, the Issuer shipped its "Ready to Drink" Cannabis Beverage Shot, THC Kiss, to the Ontario Cannabis Store ("OCS"). OCS is the only legal online retailer of recreational cannabis in Ontario.**

**THC Kiss is also available for purchase in B.C. and Saskatchewan. The Issuer is in discussion with other provinces to widen its distribution.**

**THC Kiss is a breakthrough Cannabis Beverage Shot that promises to offer a different experience compared to edibles and beverages currently available in either the grey or legal cannabis markets.**

**THC Kiss aims to be an alternative to smoking cannabis and was developed by the Issuer using a proprietary extraction methods invented by THC.**

**"We are proud to bring Canadians a true alternative to smoking cannabis," commented John Miller, president and CEO.**

**"We continue to receive very positive feedback from consumers. We have received many requests that indicate a high demand for our current products and those in development. THC BioMed continues to deliver a wide array of cannabis products to cater for all classes of cannabis consumers. In addition, all of our products are developed, manufactured and packaged by THC BioMed itself," said Mr. Miller.**

**Each 30ml bottle of THC Kiss contains 10 mg of THC.**

**Also during the period, THC announced that it had shipped Canada's first filtered Pure Cannabis Sticks to the Recreational Cannabis Market.**

**The Pure Cannabis Stick is the first cannabis pre-roll with an actual filter tip to be offered to the Canadian recreational market. Pure Cannabis Sticks are filled with pure THC BioMed**

cannabis. Pure Cannabis Sticks were shipped to Saskatchewan, with other provinces to follow.

Pure Cannabis Sticks are manufactured using THC BioMed's automated production machine. Each Pure Cannabis Stick contains 0.6 grams of cannabis and has a commercial filter.

THC BioMed is Canada's oldest active cannabis company, established in 2012. Since inception, THC has concentrated on innovative and new products not available on the grey or legal markets.

The Issuer also announced that another of its innovative and proprietary products, THC Kiss Cannabis Beverage Shot, was released for sale in Ontario.

Penelope Laine has been reappointed to the Issuer's board of directors and as a member of the Audit Committee. Ms. Laine had temporarily resigned as a director of the Issuer while Health Canada completed a standard security clearance for directors.

Ms. Laine is an experienced and licensed pharmacist and has her MBA from the University of Toronto. Ms. Laine is a graduate of the Canadian Securities Course and Trader Training Course at the Canadian Securities Institute.

2. Provide a general overview and discussion of the activities of management.

**Management continues to work on the conduct of the company's business plan, growth and harvest of product, new product testing and expansion plans.**

3. Describe and provide details of any new products or services developed or offered. For resource companies, provide details of new drilling, exploration or production programs and acquisitions of any new properties and attach any mineral or oil and gas or other reports required under Ontario securities law.

**THC Kiss, the Issuer's "Ready to Drink" Cannabis Beverage Shot is now available on the Ontario Cannabis Store.**

**THC's Pure Cannabis Sticks have shipped to the Saskatchewan Recreational Cannabis Market.**

4. Describe and provide details of any products or services that were discontinued. For resource companies, provide details of any drilling, exploration or production programs that have been amended or abandoned.

**None.**

5. Describe any new business relationships entered into between the Issuer, the Issuer's affiliates or third parties including contracts to supply products or services, joint venture agreements and licensing agreements etc. State whether the relationship is with a Related Person of the Issuer and provide details of the relationship.

**None.**

FORM 7 – MONTHLY PROGRESS REPORT

6. Describe the expiry or termination of any contracts or agreements between the Issuer, the Issuer's affiliates or third parties or cancellation of any financing arrangements that have been previously announced.

**None.**

7. Describe any acquisitions by the Issuer or dispositions of the Issuer's assets that occurred during the preceding month. Provide details of the nature of the assets acquired or disposed of and provide details of the consideration paid or payable together with a schedule of payments if applicable, and of any valuation. State how the consideration was determined and whether the acquisition was from or the disposition was to a Related Person of the Issuer and provide details of the relationship.

**None.**

8. Describe the acquisition of new customers or loss of customers.

**The Issuer has continued to register new patients.**

9. Describe any new developments or effects on intangible products such as brand names, circulation lists, copyrights, franchises, licenses, patents, software, subscription lists and trademarks.

**None.**

10. Report on any employee hiring's, terminations or lay-offs with details of anticipated length of lay-offs.

**None, except in the ordinary course of business.**

11. Report on any labour disputes and resolutions of those disputes if applicable.

**None.**

12. Describe and provide details of legal proceedings to which the Issuer became a party, including the name of the court or agency, the date instituted, the principal parties to the proceedings, the nature of the claim, the amount claimed, if any, if the proceedings are being contested, and the present status of the proceedings.

**None.**

13. Provide details of any indebtedness incurred or repaid by the Issuer together with the terms of such indebtedness.

**None.**

14. Provide details of any securities issued and options or warrants granted.

Security	Number Issued	Details of Issuance	Use of Proceeds <sup>(1)</sup>
<b>None</b>	<b>None</b>	<b>None</b>	<b>None</b>

**FORM 7 – MONTHLY PROGRESS REPORT**

(1) *State aggregate proceeds and intended allocation of proceeds.*

15. Provide details of any loans to or by Related Persons.

**None.**

16. Provide details of any changes in directors, officers or committee members.

**On September 28, the Issuer announced that Penelope Laine had been reappointed as a director and a member of the Audit Committee. Ms. Laine had temporarily resigned as a director of the Issuer while Health Canada completed a standard security clearance for directors.**

**Ms. Laine is an experienced and licensed pharmacist and has her MBA from the University of Toronto. Ms. Laine is a graduate of the Canadian Securities Course and Trader Training Course at the Canadian Securities Institute.**

17. Discuss any trends which are likely to impact the Issuer including trends in the Issuer's market(s) or political/regulatory trends.

**The Issuer's business involves certain risks and uncertainties that are inherent to the Issuer's industry. For disclosure on risks related to an investment in the Issuer, please refer to the Issuer's most recent Management's Discussion and Analysis under the titles "Financial Instruments and Risk Management" and "Other Risks and Uncertainties", which is available on SEDAR at [www.sedar.com](http://www.sedar.com).**

**The outbreak of COVID-19 has significantly increased economic uncertainty. In addition, public and private sector policies and initiatives to reduce the transmission of COVID-19, such as the imposition of travel restrictions and the adoption of remote working, have impacted our business and operations. COVID-19 is impacting our contractors' ability to provide services to us, including professional services such as accounting and auditing due to social distancing measures.**

### **Certificate of Compliance**

The undersigned hereby certifies that:

1. The undersigned is a director and senior officer of the Issuer and has been duly authorized by a resolution of the board of directors of the Issuer to sign this Certificate of Compliance.
2. As of the date hereof there were is no material information concerning the Issuer which has not been publicly disclosed.
3. The undersigned hereby certifies to CSE that the Issuer is in compliance with the requirements of applicable securities legislation (as such term is defined in National Instrument 14-101) and all CSE Requirements (as defined in CSE Policy 1).
4. All of the information in this Form 7 Monthly Progress Report is true.

**FORM 7 – MONTHLY PROGRESS REPORT**

Dated: **October 6, 2020.**

**John Miller**

Name of Director or Senior Officer

***“John Miller”***

Signature

**President and CEO**

Official Capacity

<b>Issuer Details</b>		
Name of Issuer: <b>THC BioMed Intl Ltd.</b>	For Month End <b>September</b>	Date of Report: YYYYMMDD <b>2020/10/06</b>
Issuer Address: <b>P.O. Box 20033 Towne Centre</b>		
City/Province/Postal Code: <b>Kelowna, BC V1Y 9H2</b>	Issuer Fax No.: <b>N/A</b>	Issuer Telephone No. <b>(250) 870-2512</b>
Contact Name: <b>John Miller</b>	Contact Position: <b>President &amp; CEO</b>	Contact Telephone No. <b>(250) 870-2512</b>
Contact Email Address: <b>info@thcbiomed.com</b>	Web Site Address: <b>www.thcbiomed.com</b>	